{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T17:04:27Z","timestamp":1785344667633,"version":"3.55.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY030072"],"award-info":[{"award-number":["R01EY030072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","award":["24OC0088426"],"award-info":[{"award-number":["24OC0088426"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005747","name":"AP M\u00f8ller and Chastine McKinney M\u00f8ller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005883","name":"Hertz Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010347","name":"Manufacturer Einar Willumsens Memorial Scholarship","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase and Ejnar Danielsens Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005929","name":"Danish Eye Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004954","name":"Augustinus Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010370","name":"Poul and Ellen Hertz's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006308","name":"Aarhus University Helga and Peter Kornings Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028926","name":"Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100028926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008397","name":"Velux Foundation","doi-asserted-by":"publisher","award":["00038189"],"award-info":[{"award-number":["00038189"]}],"id":[{"id":"10.13039\/100008397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["RX000444"],"award-info":[{"award-number":["RX000444"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX003050"],"award-info":[{"award-number":["BX003050"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["IK6 BX004858"],"award-info":[{"award-number":["IK6 BX004858"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012526","name":"University of Aarhus Faculty of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012526","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007605","name":"Aarhus Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007605","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008218","name":"Gangsted Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019562","name":"Synoptik Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007214","name":"Velux Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007214","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtm.2025.101620","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T17:26:55Z","timestamp":1761413215000},"page":"101620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nanobody-based gene therapy targeting complement component C3 reduces choroidal neovascularization in mice"],"prefix":"10.1016","volume":"33","author":[{"given":"Emilie Grarup","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Stax","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloriane","family":"Schnabolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyrie","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Rask-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregers Rom","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e4rbel","family":"Rohrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Louise","family":"Askou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-6350","authenticated-orcid":false,"given":"Thomas J.","family":"Corydon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101620_bib1","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet. Glob. Health"},{"key":"10.1016\/j.omtm.2025.101620_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/archophthalmol.2011.140","article-title":"Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration","volume":"129","author":"Bressler","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101620_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ajo.2011.10.016","article-title":"Incidence of legal blindness from age-related macular degeneration in Denmark: Year 2000 to 2010","volume":"153","author":"Bloch","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101620_bib4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.omtm.2025.101620_bib5","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/s41433-024-03050-z","article-title":"Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020","volume":"38","author":"Furtado","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.omtm.2025.101620_bib6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/aos.15641","article-title":"Visual acuity and causes of central visual loss in the adult Danish population 2020-2022. Results from the FORSYN study","volume":"101","author":"Bek","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101620_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.oret.2022.03.021","article-title":"Longer-term anti-VEGF therapy outcomes in neovascular age-related macular degeneration, diabetic macular edema, and vein occlusion-related macular edema: Clinical outcomes in 130 247 eyes","volume":"6","author":"Ciulla","year":"2022","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.omtm.2025.101620_bib8","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omtm.2025.101620_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12967-023-03937-7","article-title":"Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration","volume":"21","author":"Khachigian","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molimm.2014.07.012","article-title":"Relationship between the complement system, risk factors and prediction models in age-related macular degeneration","volume":"63","author":"Bora","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2015.02.032","article-title":"Age-related macular degeneration and the role of the complement system","volume":"67","author":"McHarg","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249752","article-title":"Associations between the complement system and choroidal neovascularization in wet age-related macular degeneration","volume":"21","author":"Jensen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2025.101620_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/hmg\/ddp472","article-title":"Genetic control of the alternative pathway of complement in humans and age-related macular degeneration","volume":"19","author":"Hecker","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101620_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/02713683.2011.635401","article-title":"CFB\/C2 gene polymorphisms and risk of age-related macular degeneration: A systematic review and meta-analysis","volume":"37","author":"Sun","year":"2012","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib17","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1167\/iovs.12-9587","article-title":"Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration","volume":"53","author":"Loyet","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100118","article-title":"Systemic complement activation profiles in nonexudative age-related macular degeneration: A systematic review","volume":"2","author":"Lin","year":"2022","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/bjo.2010.199216","article-title":"C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration","volume":"95","author":"Bhutto","year":"2011","journal-title":"Br. J. Ophthal."},{"key":"10.1016\/j.omtm.2025.101620_bib20","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.4049\/jimmunol.177.3.1872","article-title":"Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: Role of factor B and factor H","volume":"177","author":"Bora","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib21","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.molimm.2010.12.016","article-title":"The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization","volume":"48","author":"Rohrer","year":"2011","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12979-016-0060-5","article-title":"Higher plasma levels of complement C3a, C4a and C5a increase the risk of subretinal fibrosis in neovascular age-related macular degeneration: Complement activation in AMD","volume":"13","author":"Lechner","year":"2016","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.omtm.2025.101620_bib23","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ajo.2012.01.036","article-title":"Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration","volume":"154","author":"Singh","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101620_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molimm.2019.02.001","article-title":"Inhibition of the alternative complement pathway accelerates repair processes in the murine model of choroidal neovascularization","volume":"108","author":"Parsons","year":"2019","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.exer.2013.04.016","article-title":"Complement expression in retinal pigment epithelial cells is modulated by activated macrophages","volume":"112","author":"Luo","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.exer.2019.05.006","article-title":"The role of complement membrane attack complex in dry and wet AMD - From hypothesis to clinical trials","volume":"184","author":"Kumar-Singh","year":"2019","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib27","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101620_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101620_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj2177","article-title":"Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2022.11.016","article-title":"A Novel Bispecific Fusion Protein Targeting C3b\/C4b and VEGF in Patients With nAMD: A Randomized, Open-Label, Phase 1b Study","volume":"248","author":"Jia","year":"2023","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101620_bib31","article-title":"Validation of nanobody and antibody based in vivo tumor xenograft NIRF-imaging experiments in mice using ex vivo flow cytometry and microscopy","volume":"98","author":"Bannas","year":"2015","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.omtm.2025.101620_bib32","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3390\/jcm12082870","article-title":"Bruch\u2019s membrane: a key consideration with complement-based therapies for age-related macular degeneration","volume":"12","author":"Hammadi","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01778","article-title":"Bruch\u2019s membrane compartmentalizes complement regulation in the eye with implications for therapeutic design in age-related macular degeneration","volume":"8","author":"Clark","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2025.101620_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: A review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","article-title":"Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform","volume":"7","author":"Klarenbeek","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.omtm.2025.101620_bib37","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.omtm.2025.101620_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms9091956","article-title":"A small virus to deliver small antibodies: New targeted therapies based on AAV delivery of nanobodies","volume":"9","author":"Silva-Pilipich","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.omtm.2025.101620_bib39","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1074\/jbc.RA117.001179","article-title":"A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement","volume":"293","author":"Jensen","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101620_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtm.2025.101620_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109678","article-title":"A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia","volume":"253","author":"Chen","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib42","article-title":"Multifaceted activities of seven nanobodies against complement C4b","volume":"208","author":"Becerra","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104956","article-title":"Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies","volume":"299","author":"Struijf","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101620_bib44","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216422","article-title":"Nanobody-mediated complement activation to kill HIV-infected cells","volume":"15","author":"Pedersen","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2967\/jnumed.113.130617","article-title":"Molecular imaging with macrophage CRIg-targeting nanobodies for early and preclinical diagnosis in a mouse model of rheumatoid arthritis","volume":"55","author":"Zheng","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020298","article-title":"Nanobodies provide insight into the molecular mechanisms of the complement cascade and offer new therapeutic strategies","volume":"11","author":"Zarantonello","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.omtm.2025.101620_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4049\/jimmunol.2200952","article-title":"Bispecific complement engagers for targeted complement activation","volume":"211","author":"Pedersen","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2415060","article-title":"Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administration","volume":"16","author":"Tamburini","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.omtm.2025.101620_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.molimm.2023.12.004","article-title":"Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration","volume":"165","author":"Jindal","year":"2024","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib50","first-page":"3124","article-title":"Phase I\/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD","volume":"63","author":"Zeitz","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2021.108486","article-title":"Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys - Evidence for half-life extension by albumin","volume":"205","author":"Fuchs","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ces.2023.118521","article-title":"Multivalent nanobodies with rationally optimized linker and valency for intravitreal VEGF neutralization","volume":"270","author":"Huang","year":"2023","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10632","article-title":"A bioengineered anti-VEGF protein with high affinity and high concentration for intravitreal treatment of wet age-related macular degeneration","volume":"9","author":"Huang","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib54","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.omtm.2018.11.005","article-title":"AAV2\/8 anti-angiogenic gene therapy using single-chain antibodies inhibits murine choroidal neovascularization","volume":"13","author":"Hughes","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101620_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101145","article-title":"AAV2-antiVEGFscFv gene therapy for retinal neovascularization","volume":"31","author":"Han","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101620_bib56","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.68253","article-title":"A general approach for stabilizing nanobodies for intracellular expression","volume":"11","author":"Dingus","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.omtm.2025.101620_bib57","doi-asserted-by":"crossref","first-page":"8746","DOI":"10.1074\/jbc.RA119.012339","article-title":"A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system","volume":"295","author":"Pedersen","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101620_bib58","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1074\/jbc.M609517200","article-title":"VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family","volume":"282","author":"Esumi","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101620_bib59","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.64","article-title":"Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors","volume":"2","author":"Askou","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101620_bib60","doi-asserted-by":"crossref","first-page":"16939","DOI":"10.1074\/jbc.M808166200","article-title":"Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury","volume":"284","author":"Thurman","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omtm.2025.101620_bib61","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1084\/jem.20190009","article-title":"C3- and CR3-dependent microglial clearance protects photoreceptors in retinitis pigmentosa","volume":"216","author":"Silverman","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib62","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.exer.2008.09.005","article-title":"Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina","volume":"87","author":"Chen","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132643","article-title":"Optimization of an image-guided laser-induced choroidal neovascularization model in mice","volume":"10","author":"Gong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101620_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/iovs.63.9.11","article-title":"Animal models of choroidal neovascularization: A systematic review","volume":"63","author":"Fabian-Jessing","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib65","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/nprot.2013.135","article-title":"Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice","volume":"8","author":"Lambert","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.omtm.2025.101620_bib66","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1167\/iovs.08-2222","article-title":"A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration","volume":"50","author":"Rohrer","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib67","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1167\/iovs.10-6266","article-title":"In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography","volume":"52","author":"Giani","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.11.003","article-title":"Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization","volume":"9","author":"Schnabolk","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101620_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8120562","article-title":"Long-term systemic expression of a novel PD-1 blocking nanobody from an AAV vector provides antitumor activity without toxicity","volume":"8","author":"Silva-Pilipich","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtm.2025.101620_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150958","article-title":"Genetic passive immunization with adenoviral vector expressing chimeric nanobody-Fc molecules as therapy for genital infection caused by Mycoplasma hominis","volume":"11","author":"Burmistrova","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101620_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.704408","article-title":"A methodological approach using rAAV vectors encoding nanobody-based biologics to evaluate ARTC2.2 and P2X7 in vivo","volume":"12","author":"Gond\u00e9","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib72","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.3390\/biomedicines11123124","article-title":"Frequency and pattern of worldwide ocular gene therapy clinical trials up to 2022","volume":"11","author":"Ameri","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtm.2025.101620_bib73","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.omtm.2023.08.007","article-title":"Toward lentiviral vectors for antiangiogenic ocular gene therapy","volume":"30","author":"Askou","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101620_bib74","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","article-title":"AAV-based strategies for treatment of retinal and choroidal vascular diseases: Advances in age-related macular degeneration and diabetic retinopathy therapies","volume":"38","author":"Castro","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtm.2025.101620_bib75","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omtm.2025.101620_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq5068","article-title":"A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab","volume":"15","author":"Kearns","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2025.101620_bib77","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s40123-024-00982-3","article-title":"Pre-clinical studies of a novel bispecific fusion protein targeting C3b and VEGF in neovascular and nonexudative AMD models","volume":"13","author":"Lee","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"10.1016\/j.omtm.2025.101620_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107939","article-title":"Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration","volume":"26","author":"Wei-Zhang","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.omtm.2025.101620_bib79","first-page":"714","article-title":"Translational development of ikarovec\u2019s bicistronic geographic atrophy lead AAV vector IKC159V through capsid and delivery route optimisation","volume":"65","author":"Vaux","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101323","article-title":"Multiple gene therapy as a tool for regulating the expression of molecules involved in neovascular age-related macular degeneration","volume":"104","author":"Corydon","year":"2025","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.omtm.2025.101620_bib81","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.65.14.41","article-title":"Functional roles of pigment epithelium-derived factor in retinal degenerative and vascular disorders: A scoping review","volume":"65","author":"Jakobsen","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib82","doi-asserted-by":"crossref","first-page":"382","DOI":"10.18240\/ijo.2020.03.03","article-title":"Complement factor B knockdown by short hairpin RNA inhibits laser-induced choroidal neovascularization in rats","volume":"13","author":"Wang","year":"2020","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.omtm.2025.101620_bib83","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtm.2025.101620_bib84","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial: Safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtm.2025.101620_bib85","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/sj.mt.6300118","article-title":"A facile lentiviral vector system for expression of doxycycline-inducible shRNAs: knockdown of the pre-miRNA processing enzyme Drosha","volume":"15","author":"Aagaard","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101620_bib86","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtn.2022.02.019","article-title":"VEGFA-targeting miR-agshRNAs combine efficacy with specificity and safety for retinal gene therapy","volume":"28","author":"Alsing","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2025.101620_bib87","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1089\/hgtb.2017.079","article-title":"Suppression of choroidal neovascularization in mice by subretinal delivery of multigenic lentiviral vectors encoding anti-angiogenic microRNAs","volume":"28","author":"Askou","year":"2017","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2025.101620_bib88","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/jmg.2007.049536","article-title":"A functional CD86 polymorphism associated with asthma and related allergic disorders","volume":"44","author":"Corydon","year":"2007","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.omtm.2025.101620_bib89","first-page":"735","article-title":"Complement: activation, consequences, and control","volume":"48","author":"James","year":"1982","journal-title":"Am. J. Med. Technol."},{"key":"10.1016\/j.omtm.2025.101620_bib90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2249.1992.tb05834.x","article-title":"Activation of complement in normal serum by hydrogen peroxide and hydrogen peroxide-related oxygen radicals produced by activated neutrophils","volume":"90","author":"Shingu","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101242","article-title":"Subretinal AAV delivery of RNAi-therapeutics targeting VEGFA reduces choroidal neovascularization in a large animal model","volume":"32","author":"Haldrup","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101620_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2022.898568","article-title":"Simple autofluorescence-restrictive sorting of eGFP+ RPE cells allows reliable assessment of targeted retinal gene therapy","volume":"2","author":"Alsing","year":"2022","journal-title":"Front. Drug Deliv."},{"key":"10.1016\/j.omtm.2025.101620_bib93","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.64.7.8","article-title":"Sortilin inhibition protects neurons from degeneration in the diabetic retina","volume":"64","author":"Jakobsen","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.omtm.2025.101620_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.872536","article-title":"Structure-guided engineering of a complement component C3-binding nanobody improves specificity and adds cofactor activity","volume":"13","author":"Pedersen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101620_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136523","article-title":"Trans-corneal subretinal injection in mice and its effect on the function and morphology of the retina","volume":"10","author":"Qi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101620_bib96","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1096\/fj.13-248021","article-title":"Progressive dysfunction of the retinal pigment epithelium and retina due to increased VEGF-A levels","volume":"28","author":"Ablonczy","year":"2014","journal-title":"FASEB J."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125002153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125002153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:31:53Z","timestamp":1776198713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125002153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2329050125002153"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101620","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobody-based gene therapy targeting complement component C3 reduces choroidal neovascularization in mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101620"}}